On November 18, 2025, JP Morgan raised its price target for Eli Lilly (LLY) to $1150, reflecting increased confidence in the company's growth prospects and drug portfolio[3]. This follows ongoing positive sentiment from analysts and commentators, including Jim Cramer, who highlighted Eli Lilly's manufacturing investments and leadership in weight loss treatments[4]. LLY shares are trading at $1034.65 (+1.27%) as of 2:34PM EST, outperforming broader market indices, which are down moderately. The stock's strength today is attributed to analyst upgrades and continued enthusiasm for its obesity and diabetes drugs.